JP2017524029A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524029A5 JP2017524029A5 JP2017510528A JP2017510528A JP2017524029A5 JP 2017524029 A5 JP2017524029 A5 JP 2017524029A5 JP 2017510528 A JP2017510528 A JP 2017510528A JP 2017510528 A JP2017510528 A JP 2017510528A JP 2017524029 A5 JP2017524029 A5 JP 2017524029A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydro
- methyl
- amino
- dione
- piperidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 13
- PZFAZQUREQIODZ-LJQANCHMSA-N dvf0pr037d Chemical compound C1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@H]1N2C(=O)C=NC(C=CC3=O)=C2N3C1 PZFAZQUREQIODZ-LJQANCHMSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 10
- -1 pyrrolidin-4-ylmethyl Chemical group 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- OPQFKYZLJABARW-UHFFFAOYSA-N 1,4,7-triazatricyclo[6.3.1.04,12]dodeca-2,6,8(12),9-tetraene-5,11-dione Chemical compound N1=CC(=O)N2C=CN3C(=O)C=CC1=C32 OPQFKYZLJABARW-UHFFFAOYSA-N 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 206010018612 Gonorrhoea Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- RAMYROWBFPNRRN-OAQYLSRUSA-N (1r)-1-[(4-{[(2-oxo-2h-chromen-7-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4h,9h-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC1=CC=C2C=CC(=O)OC2=C1 RAMYROWBFPNRRN-OAQYLSRUSA-N 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- MMUYWCUHCPWDAH-UHFFFAOYSA-N 1,4-diazatricyclo[6.3.1.04,12]dodeca-2,6,8(12),9-tetraene-5,11-dione Chemical compound C1=CC(=O)N2C=CN3C(=O)C=CC1=C32 MMUYWCUHCPWDAH-UHFFFAOYSA-N 0.000 claims 2
- KLADTWZAHGRNKH-UHFFFAOYSA-N 2-[[4-(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1CC1N2C(=O)C=CC(C=CC3=O)=C2N3C1 KLADTWZAHGRNKH-UHFFFAOYSA-N 0.000 claims 2
- HIGACJLWDPTSID-UHFFFAOYSA-N 2-[[4-[(3-oxo-4H-1,4-benzothiazin-6-yl)methylamino]piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3CC2CN(CC1)CCC1NCC1=CC=C2SCC(=O)NC2=C1 HIGACJLWDPTSID-UHFFFAOYSA-N 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000005647 linker group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- UTOPGSISJNOHQK-OAHLLOKOSA-N (1r)-1-[(4-{[(4-chloro-7-oxo-6,7-dihydro-1h-pyrimido[5,4-b][1,4]oxazin-2-yl)methyl]amino}-1-piperidinyl)methyl]-1,2-dihydro-4h,9h-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC(N1)=NC(Cl)=C2C1=NC(=O)CO2 UTOPGSISJNOHQK-OAHLLOKOSA-N 0.000 claims 1
- RHGRMWGOKQLRGE-MSOLQXFVSA-N (2R)-2-[[(2S)-2-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)methyl]morpholin-4-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@@H]1OCCN(C1)C[C@H]1N2C(=O)C=CC=3C=CC(N(C1)C=32)=O)NCC(N=C1)=CC2=C1OCS2 RHGRMWGOKQLRGE-MSOLQXFVSA-N 0.000 claims 1
- GLTMIYGEUVNRHF-MOPGFXCFSA-N (2R)-2-[[(2S)-2-[[(6-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl)methylamino]methyl]morpholin-4-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3C[C@H]2CN(CCO1)C[C@@H]1CNCC1=CC(OCCO2)=C2C=C1F GLTMIYGEUVNRHF-MOPGFXCFSA-N 0.000 claims 1
- QFFDFDRUCUXPOF-MAUKXSAKSA-N (2R)-2-[[(3S)-3-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)methyl]pyrrolidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@@H]1CCN(C1)C[C@H]1N2C(=O)C=CC=3C=CC(N(C1)C=32)=O)NCC(N=C1)=CC2=C1OCS2 QFFDFDRUCUXPOF-MAUKXSAKSA-N 0.000 claims 1
- QGEMCDCWUJVVCP-GOSISDBHSA-N (2R)-2-[[4-(1,2,3-benzothiadiazol-5-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1=C2SN=NC2=CC(CNC2CCN(CC2)C[C@H]2N3C(=O)C=CC=4C=CC(N(C2)C=43)=O)=C1 QGEMCDCWUJVVCP-GOSISDBHSA-N 0.000 claims 1
- WYDAGHFQMHHLEY-OAQYLSRUSA-N (2R)-2-[[4-(1,3-dihydrofuro[3,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@H]1N2C(=O)C=CC=3C=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1COC2 WYDAGHFQMHHLEY-OAQYLSRUSA-N 0.000 claims 1
- QWTKTRPTFIUKDC-GOSISDBHSA-N (2R)-2-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=CC(CNC3CCN(CC3)C[C@H]3N4C(=O)C=CC=5N=CC(N(C3)C=54)=O)=CC=C21 QWTKTRPTFIUKDC-GOSISDBHSA-N 0.000 claims 1
- CBWKIERCSVTDRI-HXUWFJFHSA-N (2R)-2-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=CC(CNC3CCN(CC3)C[C@H]3N4C(=O)C=CC=5C=CC(N(C3)C=54)=O)=CC=C21 CBWKIERCSVTDRI-HXUWFJFHSA-N 0.000 claims 1
- WZZJTAPTHCMUTL-OAQYLSRUSA-N (2R)-2-[[4-(2,3-dihydro-1-benzofuran-5-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1=C2OCCC2=CC(CNC2CCN(CC2)C[C@H]2N3C(=O)C=CC=4C=CC(N(C2)C=43)=O)=C1 WZZJTAPTHCMUTL-OAQYLSRUSA-N 0.000 claims 1
- JVGKMLISRBCZAV-OAQYLSRUSA-N (2R)-2-[[4-(2,3-dihydro-1-benzofuran-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1=C2CCOC2=CC(CNC2CCN(CC2)C[C@H]2N3C(=O)C=CC=4C=CC(N(C2)C=43)=O)=C1 JVGKMLISRBCZAV-OAQYLSRUSA-N 0.000 claims 1
- BMVZYCHVFNYXJZ-GOSISDBHSA-N (2R)-2-[[4-(2,3-dihydrofuro[2,3-c]pyridin-5-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@H]1N2C(=O)C=CC=3N=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1OCC2 BMVZYCHVFNYXJZ-GOSISDBHSA-N 0.000 claims 1
- DUXFDBOJWHARNV-JOCHJYFZSA-N (2R)-2-[[4-(3,4-dihydro-2H-chromen-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCCC2=CC(CNC3CCN(CC3)C[C@H]3N4C(=O)C=CC=5C=CC(N(C3)C=54)=O)=CC=C21 DUXFDBOJWHARNV-JOCHJYFZSA-N 0.000 claims 1
- PEVLAFPJSPRSFM-JOCHJYFZSA-N (2R)-2-[[4-(3,4-dihydro-2H-chromen-7-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1CCOC2=CC(CNC3CCN(CC3)C[C@H]3N4C(=O)C=CC=5C=CC(N(C3)C=54)=O)=CC=C21 PEVLAFPJSPRSFM-JOCHJYFZSA-N 0.000 claims 1
- OFNLAVFKMSMGDS-LJQANCHMSA-N (2R)-2-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@@H]1CN2C(=O)C=NC3=C2N1C(=O)C=C3 OFNLAVFKMSMGDS-LJQANCHMSA-N 0.000 claims 1
- ICEFMYXDABSJEB-OAQYLSRUSA-N (2R)-2-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@H]1N2C(=O)C=CC(C=CC3=O)=C2N3C1 ICEFMYXDABSJEB-OAQYLSRUSA-N 0.000 claims 1
- QVFCTNFLPSJPQN-LJQANCHMSA-N (2R)-2-[[4-(3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound S1CCNC2=NC(CNC3CCN(CC3)C[C@H]3N4C(=O)C=CC=5C=CC(N(C3)C=54)=O)=CC=C21 QVFCTNFLPSJPQN-LJQANCHMSA-N 0.000 claims 1
- CLYVNLVGBVTDSA-HSZRJFAPSA-N (2R)-2-[[4-(5,6,7,8-tetrahydroisoquinolin-3-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1CCCC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@H]1N2C(=O)C=CC(C=CC3=O)=C2N3C1 CLYVNLVGBVTDSA-HSZRJFAPSA-N 0.000 claims 1
- ZOXCLKYRAFCQRK-JOCHJYFZSA-N (2R)-2-[[4-(6,7-dihydro-5H-cyclopenta[c]pyridin-3-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@H]1N2C(=O)C=CC=3C=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1CCC2 ZOXCLKYRAFCQRK-JOCHJYFZSA-N 0.000 claims 1
- KIWAKXFQIRVLDG-MRXNPFEDSA-N (2R)-2-[[4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@@H]1CN2C(=O)C=NC=3C=CC(N1C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 KIWAKXFQIRVLDG-MRXNPFEDSA-N 0.000 claims 1
- MMKKZZRTGQEWMB-GOSISDBHSA-N (2R)-2-[[4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@H]1N2C(=O)C=CC=3C=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 MMKKZZRTGQEWMB-GOSISDBHSA-N 0.000 claims 1
- FZNZGXHLNWWFRD-QGZVFWFLSA-N (2R)-2-[[4-[(4-fluoro-1H-benzimidazol-2-yl)methylamino]piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC(N1)=NC2=C1C=CC=C2F FZNZGXHLNWWFRD-QGZVFWFLSA-N 0.000 claims 1
- VTAVAXMXOYKAEA-QGZVFWFLSA-N (2R)-2-[[4-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl)methylamino]piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=C1C=C(CNC1CCN(C[C@H]3N4C=5N(C(C=NC=5C=CC4=O)=O)C3)CC1)C=C2F VTAVAXMXOYKAEA-QGZVFWFLSA-N 0.000 claims 1
- UKPSUEHNNCZJMF-LJQANCHMSA-N (2R)-2-[[4-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl)methylamino]piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=C1C=C(CNC1CCN(C[C@H]3N4C=5N(C(C=CC=5C=CC4=O)=O)C3)CC1)C=C2F UKPSUEHNNCZJMF-LJQANCHMSA-N 0.000 claims 1
- SOYYVDIBAUMRSG-QGZVFWFLSA-N (2R)-2-[[4-[(6-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl)methylamino]piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=CC(N=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC1=CC(OCCO2)=C2C=C1F SOYYVDIBAUMRSG-QGZVFWFLSA-N 0.000 claims 1
- XRKPIHKEOCFNBS-MRXNPFEDSA-N (2R)-2-[[4-[(7-chloro-3-oxo-4H-pyrido[3,2-b][1,4]oxazin-6-yl)methylamino]piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC1=NC(NC(=O)CO2)=C2C=C1Cl XRKPIHKEOCFNBS-MRXNPFEDSA-N 0.000 claims 1
- IFLSEVONAYZDGL-MRXNPFEDSA-N (2R)-2-[[4-[(7-oxo-8H-pyrimido[5,4-b][1,4]thiazin-2-yl)methylamino]piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=CC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC1=NC=C2SCC(=O)N=C2N1 IFLSEVONAYZDGL-MRXNPFEDSA-N 0.000 claims 1
- GLPRDZSYLBBDLT-GOSISDBHSA-N (2R)-2-[[4-methyl-4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1CN(C[C@H]2N3C=4N(C(C=CC=4C=CC3=O)=O)C2)CCC1(C)NCC(N=C1)=CC2=C1OCS2 GLPRDZSYLBBDLT-GOSISDBHSA-N 0.000 claims 1
- GXAMZVLKELUPES-MRXNPFEDSA-N (3R)-3-[[4-(2,1,3-benzothiadiazol-5-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1=CC2=NSN=C2C=C1CNC(CC1)CCN1C[C@H]1N2C(=O)C=NC(C=CC3=O)=C2N3C1 GXAMZVLKELUPES-MRXNPFEDSA-N 0.000 claims 1
- LKTSUDBZUBEDTQ-GOSISDBHSA-N (3R)-3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=CC(CNC3CCN(CC3)C[C@H]3N4C(=O)C=NC=5C=CC(N(C3)C=54)=O)=CC=C21 LKTSUDBZUBEDTQ-GOSISDBHSA-N 0.000 claims 1
- GTOBAXKBBVOAQH-GOSISDBHSA-N (3R)-3-[[4-(3,4-dihydro-2H-[1,4]oxathiepino[2,3-c]pyridin-8-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound S1CCCOC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@H]1N2C(=O)C=NC(C=CC3=O)=C2N3C1 GTOBAXKBBVOAQH-GOSISDBHSA-N 0.000 claims 1
- TUHWOZWYEBHVFD-OAHLLOKOSA-N (3R)-3-[[4-([1,2,5]thiadiazolo[3,4-b]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1=NC2=NSN=C2C=C1CNC(CC1)CCN1C[C@H]1N2C(=O)C=NC(C=CC3=O)=C2N3C1 TUHWOZWYEBHVFD-OAHLLOKOSA-N 0.000 claims 1
- OKUFHCDPAKULIQ-MRXNPFEDSA-N (3R)-3-[[4-([1,3]oxathiolo[4,5-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@H]1N2C(=O)C=NC=3C=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1SCO2 OKUFHCDPAKULIQ-MRXNPFEDSA-N 0.000 claims 1
- CCNWBTVQMPIXKO-MRXNPFEDSA-N (3R)-3-[[4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@H]1N2C(=O)C=NC=3C=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 CCNWBTVQMPIXKO-MRXNPFEDSA-N 0.000 claims 1
- BTPHCQKZRYEOES-MRXNPFEDSA-N (3R)-3-[[4-[(3-oxo-4H-pyrido[3,2-b][1,4]thiazin-6-yl)methylamino]piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=NC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC1=CC=C2SCC(=O)NC2=N1 BTPHCQKZRYEOES-MRXNPFEDSA-N 0.000 claims 1
- XIZMQMZFYXGFKF-QGZVFWFLSA-N (3R)-3-[[4-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-6-yl)methylamino]piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=C1C=CC(CNC1CCN(C[C@H]3N4C=5N(C(C=CC=5N=CC4=O)=O)C3)CC1)=C2F XIZMQMZFYXGFKF-QGZVFWFLSA-N 0.000 claims 1
- YUXWDRXDQJRIHT-QGZVFWFLSA-N (3R)-3-[[4-[(5-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl)methylamino]piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC2=C1C=C(CNC1CCN(C[C@H]3N4C=5N(C(C=CC=5N=CC4=O)=O)C3)CC1)C=C2F YUXWDRXDQJRIHT-QGZVFWFLSA-N 0.000 claims 1
- FMRCSLFHMVCMST-QGZVFWFLSA-N (3R)-3-[[4-[(6-fluoro-2,3-dihydro-1,4-benzodioxin-7-yl)methylamino]piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound N12C(=O)C=NC(C=CC3=O)=C1N3C[C@H]2CN(CC1)CCC1NCC1=CC(OCCO2)=C2C=C1F FMRCSLFHMVCMST-QGZVFWFLSA-N 0.000 claims 1
- CCNWBTVQMPIXKO-INIZCTEOSA-N (3S)-3-[[4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C([C@@H]1N2C(=O)C=NC=3C=CC(N(C1)C=32)=O)N(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 CCNWBTVQMPIXKO-INIZCTEOSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- UDGKZGLPXCRRAM-UHFFFAOYSA-N 1,2,5-thiadiazole Chemical compound C=1C=NSN=1 UDGKZGLPXCRRAM-UHFFFAOYSA-N 0.000 claims 1
- MMKKZZRTGQEWMB-UHFFFAOYSA-N 1-({4-[([1,3]oxathiolo[5,4-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-4h,9h-imidazo[1,2,3-ij]-1,8-naphthyridine-4,9-dione Chemical compound C1N(C=23)C(=O)C=CC=2C=CC(=O)N3C1CN(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 MMKKZZRTGQEWMB-UHFFFAOYSA-N 0.000 claims 1
- RPTVNNSZTGSBJN-UHFFFAOYSA-N 2-[[4-(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1CC1CN2C(=O)C=NC3=C2N1C(=O)C=C3 RPTVNNSZTGSBJN-UHFFFAOYSA-N 0.000 claims 1
- WHYWOATXBUMODD-UHFFFAOYSA-N 3-[[4-(2,3-dihydro-[1,4]dioxino[2,3-c]pyridin-7-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound O1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1CC1N2C(=O)C=NC(C=CC3=O)=C2N3C1 WHYWOATXBUMODD-UHFFFAOYSA-N 0.000 claims 1
- CCNWBTVQMPIXKO-UHFFFAOYSA-N 3-[[4-([1,3]oxathiolo[5,4-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione Chemical compound C1N(C=23)C(=O)C=CC=2N=CC(=O)N3C1CN(CC1)CCC1NCC(N=C1)=CC2=C1OCS2 CCNWBTVQMPIXKO-UHFFFAOYSA-N 0.000 claims 1
- IDEYQVRMVSQTQG-UHFFFAOYSA-N 7-[[[1-[(5,11-dioxo-1,4-diazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-trien-2-yl)methyl]piperidin-4-yl]amino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound O1CCOC(C(=C2)C#N)=C1C=C2CNC(CC1)CCN1CC1N2C(=O)C=CC(C=CC3=O)=C2N3C1 IDEYQVRMVSQTQG-UHFFFAOYSA-N 0.000 claims 1
- IBUFOAQZTPVRGC-LJQANCHMSA-N 7-[[[1-[[(2R)-5,11-dioxo-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-trien-2-yl]methyl]piperidin-4-yl]amino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound O1CCOC(C(=C2)C#N)=C1C=C2CNC(CC1)CCN1C[C@@H]1CN2C(=O)C=NC3=C2N1C(=O)C=C3 IBUFOAQZTPVRGC-LJQANCHMSA-N 0.000 claims 1
- XGDVNSOMPMIGMO-LJQANCHMSA-N 7-[[[1-[[(3R)-5,11-dioxo-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-trien-3-yl]methyl]piperidin-4-yl]amino]methyl]-2,3-dihydro-1,4-benzodioxine-5-carbonitrile Chemical compound O1CCOC(C(=C2)C#N)=C1C=C2CNC(CC1)CCN1C[C@H]1N2C(=O)C=NC(C=CC3=O)=C2N3C1 XGDVNSOMPMIGMO-LJQANCHMSA-N 0.000 claims 1
- RPTVNNSZTGSBJN-QGZVFWFLSA-N O1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@@H]1CN2C(=O)C=NC3=C2N1C(=O)C=C3 Chemical compound O1CCOC(C=N2)=C1C=C2CNC(CC1)CCN1C[C@@H]1CN2C(=O)C=NC3=C2N1C(=O)C=C3 RPTVNNSZTGSBJN-QGZVFWFLSA-N 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000002527 bicyclic carbocyclic group Chemical group 0.000 claims 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 125000006413 ring segment Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 229960003405 ciprofloxacin Drugs 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- NUOCBVKZOWSPGI-UHFFFAOYSA-N Cl.N1=CC(=O)N2C=CN3C(=O)C=CC1=C32 Chemical compound Cl.N1=CC(=O)N2C=CN3C(=O)C=CC1=C32 NUOCBVKZOWSPGI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- PZFAZQUREQIODZ-UHFFFAOYSA-N O=C(C=C1)N(CC(CN(CC2)CCC2NCc(nc2)cc3c2OCCC3)N23)C2=C1N=CC3=O Chemical compound O=C(C=C1)N(CC(CN(CC2)CCC2NCc(nc2)cc3c2OCCC3)N23)C2=C1N=CC3=O PZFAZQUREQIODZ-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462040488P | 2014-08-22 | 2014-08-22 | |
| US62/040,488 | 2014-08-22 | ||
| PCT/IB2015/056325 WO2016027249A1 (en) | 2014-08-22 | 2015-08-20 | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019115462A Division JP2019189629A (ja) | 2014-08-22 | 2019-06-21 | 淋菌感染を治療するための三環式含窒素化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524029A JP2017524029A (ja) | 2017-08-24 |
| JP2017524029A5 true JP2017524029A5 (enExample) | 2019-01-31 |
| JP6546654B2 JP6546654B2 (ja) | 2019-07-17 |
Family
ID=54072911
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510528A Active JP6546654B2 (ja) | 2014-08-22 | 2015-08-20 | 淋菌感染を治療するための三環式含窒素化合物 |
| JP2019115462A Withdrawn JP2019189629A (ja) | 2014-08-22 | 2019-06-21 | 淋菌感染を治療するための三環式含窒素化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019115462A Withdrawn JP2019189629A (ja) | 2014-08-22 | 2019-06-21 | 淋菌感染を治療するための三環式含窒素化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10702521B2 (enExample) |
| EP (2) | EP3639824A1 (enExample) |
| JP (2) | JP6546654B2 (enExample) |
| KR (1) | KR20170043603A (enExample) |
| CN (2) | CN106659717B (enExample) |
| AR (1) | AR101674A1 (enExample) |
| AU (1) | AU2015304847B2 (enExample) |
| BR (1) | BR112017003705B1 (enExample) |
| CA (1) | CA2958800C (enExample) |
| CL (1) | CL2017000391A1 (enExample) |
| CO (1) | CO2017001658A2 (enExample) |
| CR (1) | CR20170069A (enExample) |
| DO (1) | DOP2017000049A (enExample) |
| EA (1) | EA031589B1 (enExample) |
| ES (1) | ES2759303T3 (enExample) |
| IL (1) | IL250251A0 (enExample) |
| MX (1) | MX2017002321A (enExample) |
| PE (1) | PE20170501A1 (enExample) |
| PH (1) | PH12017500315A1 (enExample) |
| SG (1) | SG11201700566SA (enExample) |
| TW (1) | TW201618779A (enExample) |
| WO (1) | WO2016027249A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016027249A1 (en) * | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
| AU2017276627A1 (en) * | 2016-06-08 | 2018-12-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | New antibacterial compounds |
| WO2018108671A1 (en) | 2016-12-16 | 2018-06-21 | Basf Se | Pesticidal compounds |
| EP3946342A1 (en) * | 2019-04-03 | 2022-02-09 | GlaxoSmithKline Intellectual Property Development Limited | Gepotidacin for use in the treatment of bacterial urinary tract infections |
| US20220184071A1 (en) * | 2019-04-03 | 2022-06-16 | Glaxosmithkline Intellectual Property Development Limited | Gepotidacin for use in the treatment of bacterial urinary tract infections |
| GB201909191D0 (en) * | 2019-06-26 | 2019-08-07 | Ucb Biopharma Sprl | Therapeutic agents |
| US20220257615A1 (en) * | 2019-07-05 | 2022-08-18 | Glaxosmithkline Intellectual Property Development Limied | Combination for the treatment of infections caused by mycoplasma genitalium |
| MX2022006700A (es) | 2019-12-02 | 2022-09-02 | Storm Therapeutics Ltd | Compuestos poliheterociclicos como inhibidores de mettl3. |
| JP2023528560A (ja) * | 2020-04-02 | 2023-07-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | ゲポチダシンを用いて淋菌感染症を治療するためのレジメン |
| WO2021219671A1 (en) * | 2020-04-28 | 2021-11-04 | Noorik Biopharmaceuticals Ag | Treatment of pulmonary complications of coronavirus infections |
| WO2021219637A1 (en) | 2020-04-29 | 2021-11-04 | Glaxosmithkline Intellectual Property Development Limited | Crystalline forms of gepotidacin |
| EP4288035A1 (en) * | 2021-02-05 | 2023-12-13 | GlaxoSmithKline Intellectual Property Development Limited | Oral solid dose formulations |
| EP4316463A1 (en) | 2022-08-02 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Novel formulation |
| JP2025532252A (ja) | 2022-09-26 | 2025-09-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 処置方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA931343B (en) | 1992-03-06 | 1993-09-24 | Akzo Nv | 1,4-dioxino(2,3-b)pyridine derivatives. |
| DE69423383T2 (de) * | 1993-05-13 | 2000-08-24 | American Cyanamid Co., Wayne | Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken |
| GB0207450D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| EP1306038B1 (en) | 2000-07-21 | 2005-12-21 | Ljudmila Petrovna Maljuk | Plate for a stand-up meal |
| DE60125373T2 (de) | 2000-07-26 | 2007-10-18 | Smithkline Beecham P.L.C., Brentford | Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung |
| IL155092A0 (en) | 2000-09-29 | 2003-10-31 | Glaxo Group Ltd | Compounds useful in the treatment of inflammatory diseases |
| FR2816618B1 (fr) | 2000-11-15 | 2002-12-27 | Aventis Pharma Sa | Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent |
| GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| EP1345903A1 (en) | 2000-12-21 | 2003-09-24 | Ciba SC Holding AG | Crystalline forms of cerivastatin sodium |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0118238D0 (en) | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
| AU2002350217A1 (en) | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| WO2003064421A1 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine derivatives |
| WO2003064431A2 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| AR040335A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto |
| TW200409637A (en) | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
| GB0217294D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicaments |
| FR2844268B1 (fr) | 2002-09-11 | 2004-10-22 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent |
| FR2844270B1 (fr) | 2002-09-11 | 2006-05-19 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent |
| AU2003301414B8 (en) | 2002-10-10 | 2010-06-17 | Morphochem Aktiengesellschaft Fur Kombinatorische Chemie | Novel compounds with antibacterial activity |
| DE60331849D1 (de) | 2002-11-05 | 2010-05-06 | Glaxosmithkline Llc | Antibakterielle wirkstoffe |
| AU2003291227A1 (en) | 2002-11-05 | 2004-06-07 | Smithkline Beecham Corporation | Antibacterial agents |
| TW200427688A (en) | 2002-12-18 | 2004-12-16 | Glaxo Group Ltd | Antibacterial agents |
| TW200507841A (en) | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
| FR2852954B1 (fr) | 2003-03-28 | 2006-07-14 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| DE10316081A1 (de) | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| WO2004104000A1 (ja) | 2003-05-23 | 2004-12-02 | Japan Tobacco Inc. | トリサイクリック縮合環化合物およびその医薬用途 |
| FR2858619B1 (fr) | 2003-08-08 | 2006-12-22 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2867472B1 (fr) | 2004-03-12 | 2008-07-18 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
| FR2872164B1 (fr) | 2004-06-29 | 2006-11-17 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1773831A1 (en) | 2004-07-08 | 2007-04-18 | Glaxo Group Limited | Antibacterial agents |
| WO2006010040A2 (en) | 2004-07-09 | 2006-01-26 | Glaxo Group Limited | Antibacterial agents |
| EP1773343A4 (en) | 2004-07-13 | 2009-05-13 | Glaxo Group Ltd | ANTIBACTERIAL AGENTS |
| US20070270417A1 (en) | 2004-07-22 | 2007-11-22 | Glaxo Group Limited | Antibacterial Agents |
| DE602005024151D1 (de) | 2004-08-02 | 2010-11-25 | Glaxo Group Ltd | Antibakterielle mittel |
| US20070161627A1 (en) | 2004-08-09 | 2007-07-12 | Miller William H | Antibacterial agents |
| DE102004041163A1 (de) | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| JP4887297B2 (ja) | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | 新規二環式抗生物質 |
| ATE466857T1 (de) | 2004-10-05 | 2010-05-15 | Actelion Pharmaceuticals Ltd | Neue piperidin-antibiotika |
| WO2006046552A1 (ja) | 2004-10-27 | 2006-05-04 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| WO2006081179A1 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| US7605169B2 (en) | 2005-01-25 | 2009-10-20 | Glaxo Group Limited | Antibacterial agents |
| WO2006081178A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| WO2006081182A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| WO2006081289A2 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| WO2006099884A1 (en) | 2005-03-24 | 2006-09-28 | Actelion Percurex Ag | Beta-aminoalcohol antibiotics |
| EP1863483A4 (en) | 2005-03-31 | 2010-03-31 | Janssen Pharmaceutica Nv | Bicyclic pyrazole compounds as anti-bacteriostatic agents |
| AR053602A1 (es) | 2005-05-03 | 2007-05-09 | Smithkline Beecham Corp | Compuesto de 2- arilamino -4-oxo-1,3-tiazol-5(4h)- substituido, composicion farmaceutica que lo comprende, proceso para prepararla y uso del compuesto para preparar un medicamento |
| AU2006250987A1 (en) | 2005-05-24 | 2006-11-30 | Astrazeneca Ab | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| EP1888574B1 (en) | 2005-05-25 | 2009-09-02 | Actelion Pharmaceuticals Ltd. | New antibiotic derivatives |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| EP1900732A4 (en) | 2005-06-24 | 2009-11-18 | Toyama Chemical Co Ltd | NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF |
| WO2007016610A2 (en) | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | Antibacterial agents |
| EP1954697B1 (en) | 2005-10-21 | 2010-02-24 | Glaxo Group Limited | Peri condensed tricyclic compounds useful as antibacterial agents |
| JP2009518409A (ja) | 2005-12-06 | 2009-05-07 | メルク エンド カムパニー インコーポレーテッド | モルホリンカルボキサミドプロキネチシン受容体アンタゴニスト |
| US20070185153A1 (en) | 2005-12-22 | 2007-08-09 | Nathalie Cailleau | Compounds |
| EP2001887B1 (en) | 2006-04-06 | 2010-09-15 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
| EP2007377A4 (en) | 2006-04-06 | 2011-08-17 | Glaxo Group Ltd | ANTIBACTERIAL ACTIVE SUBSTANCES |
| GB0608263D0 (en) | 2006-04-26 | 2006-06-07 | Glaxo Group Ltd | Compounds |
| US20100256124A1 (en) | 2006-06-09 | 2010-10-07 | David Thomas Davies | Substituted 1-Methyl-1H-Quinolin-2-Ones And 1-Methyl-1H-1,5-Naphthyridin-2-Ones As Antibacterials |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| EP1992628A1 (en) | 2007-05-18 | 2008-11-19 | Glaxo Group Limited | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones |
| CA2684659C (en) * | 2007-04-20 | 2015-11-24 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| MX2010012732A (es) * | 2008-05-23 | 2010-12-07 | Glaxo Group Ltd | Compuestos que contienen nitrogeno triciclico y su uso como antibacterianos. |
| WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
| WO2016027249A1 (en) * | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
-
2015
- 2015-08-20 WO PCT/IB2015/056325 patent/WO2016027249A1/en not_active Ceased
- 2015-08-20 PE PE2017000215A patent/PE20170501A1/es not_active Application Discontinuation
- 2015-08-20 EP EP19197439.3A patent/EP3639824A1/en not_active Withdrawn
- 2015-08-20 JP JP2017510528A patent/JP6546654B2/ja active Active
- 2015-08-20 AU AU2015304847A patent/AU2015304847B2/en not_active Ceased
- 2015-08-20 MX MX2017002321A patent/MX2017002321A/es unknown
- 2015-08-20 CR CR20170069A patent/CR20170069A/es unknown
- 2015-08-20 US US15/505,715 patent/US10702521B2/en active Active
- 2015-08-20 SG SG11201700566SA patent/SG11201700566SA/en unknown
- 2015-08-20 BR BR112017003705-0A patent/BR112017003705B1/pt active IP Right Grant
- 2015-08-20 AR ARP150102680A patent/AR101674A1/es unknown
- 2015-08-20 EA EA201790442A patent/EA031589B1/ru not_active IP Right Cessation
- 2015-08-20 KR KR1020177007353A patent/KR20170043603A/ko not_active Withdrawn
- 2015-08-20 EP EP15762763.9A patent/EP3182973B1/en active Active
- 2015-08-20 TW TW104127098A patent/TW201618779A/zh unknown
- 2015-08-20 ES ES15762763T patent/ES2759303T3/es active Active
- 2015-08-20 CN CN201580045166.8A patent/CN106659717B/zh active Active
- 2015-08-20 CA CA2958800A patent/CA2958800C/en active Active
- 2015-08-20 CN CN201910738641.XA patent/CN110403939A/zh active Pending
-
2017
- 2017-01-23 IL IL250251A patent/IL250251A0/en unknown
- 2017-02-16 CL CL2017000391A patent/CL2017000391A1/es unknown
- 2017-02-21 DO DO2017000049A patent/DOP2017000049A/es unknown
- 2017-02-21 CO CONC2017/0001658A patent/CO2017001658A2/es unknown
- 2017-02-21 PH PH12017500315A patent/PH12017500315A1/en unknown
-
2019
- 2019-06-21 JP JP2019115462A patent/JP2019189629A/ja not_active Withdrawn
-
2020
- 2020-07-01 US US16/918,084 patent/US11229646B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524029A5 (enExample) | ||
| CA2684659C (en) | Tricyclic nitrogen containing compounds as antibacterial agents | |
| AU2015304847B2 (en) | Tricyclic nitrogen containing compounds for treating Neisseria gonorrhoea infection | |
| US8071592B2 (en) | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | |
| CA3094690A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| AU2013361127A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| WO2012049277A1 (en) | Cxcr4 receptor antagonists | |
| AU2013312477A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| JP2006511622A (ja) | 抗菌剤 | |
| DK3097083T3 (en) | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
| US20100087424A1 (en) | Tricyclic nitrogen containing heterocycles as antibacterial agents | |
| US20100184751A1 (en) | Heterocyclic compounds for the treatment of tuberculosis | |
| TW201632533A (zh) | 抗肺結核病的硝基咪唑衍生物 | |
| JP2011509274A (ja) | 三環系窒素化合物および抗菌剤としてのその使用 | |
| CA3182500A1 (en) | Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5 | |
| TW202400612A (zh) | 作為HPK1抑制劑之四氫吡啶并[3,4-d]嘧啶化物 | |
| TWI570124B (zh) | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |